Autolus Therapeutics Changes Auditor from EY UK to EY US, Citing No Disagreements
AUTL sits 40% above its 52-week low of $1.15.
Summary
Autolus Therapeutics changed its independent auditor from EY UK to EY US, a move within the same global firm, with no reported disagreements but a reminder of prior material weaknesses in internal controls.
Key Events · Corporate Governance and Compliance · AUTL
-
Auditor Dismissal
Autolus Therapeutics dismissed Ernst & Young LLP (UK) as its independent registered public accounting firm on April 14, 2026.
-
New Auditor Appointment
The Audit Committee approved the engagement of Ernst & Young LLP (US) as the new independent registered public accounting firm, effective immediately for the fiscal year ending December 31, 2026.
-
No Accounting Disagreements
The company reported no disagreements with EY UK on accounting principles or practices that would have impacted their audit reports for the past two fiscal years.
-
Prior Material Weakness Noted
The filing referenced a previously disclosed material weakness in internal controls over financial reporting as of March 31, 2024, which was initially reported in a Form 10-Q.
Analysis · AUTL · Life Sciences
Autolus Therapeutics dismissed Ernst & Young LLP (UK) and appointed Ernst & Young LLP (US) as its new independent registered public accounting firm. While the change is within the same global firm and no disagreements on accounting principles or practices were reported, the filing reminds investors of previously disclosed material weaknesses in internal controls as of March 31, 2024. This transition, though not indicative of a dispute, warrants attention as the company navigates its financial health and product launches.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1594 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AUTL was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $396.6M. The 52-week trading range was $1.15 to $2.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.